Edition:
United Kingdom

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

75.80EUR
15 Dec 2017
Change (% chg)

€-0.60 (-0.79%)
Prev Close
€76.40
Open
€76.00
Day's High
€76.50
Day's Low
€75.45
Volume
98,841
Avg. Vol
80,456
52-wk High
€82.10
52-wk Low
€51.85

Chart for

About

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease,... (more)

Overall

Beta: 0.34
Market Cap(Mil.): €4,419.91
Shares Outstanding(Mil.): 55.95
Dividend: 0.80
Yield (%): 1.01

Financials

  Industry Sector
P/E (TTM): -- 32.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-Diasorin Receives CE Mark For A New Bordetella Molecular Diagnostic Test

* RECEIVES CE MARK FOR A NEW BORDETELLA MOLECULAR DIAGNOSTIC TEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

12 Dec 2017

BRIEF-DiaSorin Q3 net profit up at EUR 29.3‍​ mln, confirms 2017 guidance

* Q3 NET REVENUE EUR ‍​149.4 MILLION VERSUS EUR 147.0 MILLION YEAR AGO

09 Nov 2017

BRIEF-Diasorin revises its FY 2019 guidance

* INCREASES ITS 2019 REVENUE GUIDANCE TO ABOUT EUR 775 MILLION FROM EUR 735 MILLION

29 Sep 2017

BRIEF-DiaSorin ‍completes acquisition of Elisa immunodiagnostic business portfolio​

* ‍COMPLETES ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

29 Sep 2017

BRIEF-DiaSorin ‍earns CE-mark extending sample claims for its Simplexa HSV 1&2 kit​

* ‍EARNS CE-MARK EXTENDING SAMPLE CLAIMS FOR DIASORIN MOLECULAR'S SIMPLEXA HSV 1 & 2 KIT​

21 Sep 2017

BRIEF-DiaSorin Q2 net profit up at EUR 33.6 mln

* Q2 NET PROFIT EUR 33.6 MILLION VERSUS EUR 29.4 MILLION YEAR AGO

03 Aug 2017

BRIEF-DiaSorin launches three primer pairs for use in molecular testing

* LAUNCHES 3 PRIMER PAIRS FOR USE IN MOLECULAR TESTING: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, AND GROUP G STREPTOCOCCUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

28 Jul 2017

BRIEF-Diasorin to acquire ELISA immunodiagnostic business portfolio from Siemens Healthineers

* TO ACQUIRE ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS

25 Jul 2017

BRIEF-DiaSorin launches test Iam CBFB-MYH11 for acute myeloid leukemia

* LAUNCHES MOLECULAR DIAGNOSTIC TEST IAM CBFB-MYH11 (AVAILABLE WORLDWIDE EXCEPT UNITED STATES) FOR DIAGNOSIS OF ONE OF THE GENETIC CAUSES OF ACUTE MYELOID LEUKEMIA Source text: http://reut.rs/2tZeE1p Further company coverage: (Gdynia Newsroom)

10 Jul 2017

BRIEF-Diasorin presents its 2017-2019 industrial plan

* DIASORIN WILL CONTINUE TO LOOK FOR POTENTIAL ACQUISITIONS, FOCUSING ON TARGET THAT WILL ALLOW GROUP TO EXPAND ITS CUSTOMER BASE AND ITS PRESENCE IN STRATEGIC MARKETS

26 Jun 2017

Earnings vs. Estimates